FIELD: medicine.
SUBSTANCE: group of inventions discloses a combination of antibody to CD20 type II, which is formed by glycoengineering humanised antibody B-Ly1, where the humanised antibody B-Ly1 has a variable region of heavy chain (VH) SEQ ID No. 7 and light chain variable region (VL) SEQ ID No. 20, and chemotherapeutic agents selected from a group comprising cyclophosphamide, vincristine and doxorubicin, applicable for treating B-cell non-Hodgkin Lymphoma, as well as use of the named antibody for preparing a drug.
EFFECT: group of inventions is effective in treating of B-cell non-Hodgkin lymphoma.
5 cl, 4 dwg, 3 tbl, 4 ex
